Cardiac Action Potential

The cardiac action potential is the transient electrical waveform that drives cardiomyocyte contraction by coordinating the sequential opening and closing of ion channels across the sarcolemma. Also called the myocardial action potential, cardiac AP, or simply the action potential, it is the fundamental electrical event underlying every heartbeat. The cardiac action potential is divided into five phases based on the predominant ion currents: phase 0 (rapid depolarization, Na⁺ influx via Nav1.5 ), phase 1 (early repolarization, transient outward K⁺ current Iₜₒ), phase 2 (plateau, L-type Ca²⁺ current I_Ca,L balancing delayed rectifier K⁺ currents), phase 3 (repolarization, rapid I_Kr and slow I_Ks), and phase 4 (resting potential, maintained by I_K1 and Na⁺/K⁺-ATPase) ^[1]D5[3]D5.

Classification of Action Potential Abnormalities

Abnormalities in action potential duration (APD) or morphology are central to arrhythmogenesis. These are classified by the phase affected and the net ionic current imbalance ^[8]D5[9]D5.

These AP abnormalities are the mechanistic basis for inherited cardiac channelopathies, LQTS, SQTS, Brugada syndrome , and CPVT, which collectively predispose to sudden cardiac death in structurally normal hearts ^{[1]D5[2]D5[6]D5}. Drug-induced AP changes, such as loperamide's blockade of I_Kr and I_Na, produce both QT prolongation and QRS widening ^[4]D5. Antiarrhythmic drugs exert their effects by targeting specific phases of the AP, as organized by the Vaughan Williams and modernized Oxford classifications ^[3]D5.

Understanding the normal cardiac action potential and its variants is the prerequisite for interpreting the epidemiology , risk factors, and clinical presentations that follow.

Pearl: Classification of AP abnormalities by ionic mechanism provides the framework for understanding antiarrhythmic drug action and arrhythmogenesis.

The clinical impact of these disorders is defined by their epidemiology . Inherited cardiac channelopathies, such as long QT syndrome, Brugada syndrome , and short QT syndrome, collectively account for a substantial proportion of sudden cardiac death in young individuals with structurally normal hearts. Brugada syndrome has an estimated incidence of 1:2000 and is responsible for up to 20% of sudden arrhythmic deaths in those without structural heart disease ^[18]D5. Prevalence is higher in Southeast Asian populations, where the condition is endemic. The long QT syndrome affects approximately 1 in 2000 live births, with a female predominance ^[10]D5.

Risk Factors

Risk factors for cardiac action potential abnormalities are both genetic and environmental. Pathogenic variants in genes encoding cardiac ion channels or their regulatory subunits are the primary drivers. For example, mutations in SCN5A (the cardiac sodium channel gene) cause loss‑ or gain‑of‑function that underlies Brugada syndrome, long QT syndrome, and progressive cardiac conduction disease ^[17]D5. Common polymorphisms also confer modest risk: the KCNQ1 rs2237892 C allele increases the odds of type 2 diabetes by 32% (OR 1.32, 95%) ^[16]B3a, and the SGK1 gene variant (prevalence 3-5% in Caucasians, ~10% in Africans) is associated with hypertension , obesity, and stroke ^[14]D5.

Environmental triggers include fever, which is a common precipitant of arrhythmias in children with Brugada syndrome ^[18]D5. Cocaine, by blocking sodium and potassium channels, induces a wide spectrum of arrhythmias ^[15]D5. Aging and myocardial infarction increase the prevalence of cardiac fibroblasts, which express BKCa channels that can depolarize adjacent cardiomyocytes and promote arrhythmogenesis ^[13]D5.

Temporal trends suggest an increasing recognition of inherited channelopathies due to wider genetic testing, but true incidence may be stable. The next section dissects the molecular mechanisms by which these risk factors perturb the cardiac action potential.

Pearl: In a young patient with unexplained syncope or sudden death, consider a channelopathy, Brugada syndrome has a 1:2000 prevalence and a 20% contribution to sudden death in structurally normal hearts; fever is a dangerous trigger in children ^[18]D5.

These risk factors, genetic, autoimmune, inflammatory, and iatrogenic, converge on a common final pathway: disruption of the ionic currents that generate the cardiac action potential. The action potential is a coordinated sequence of five phases (0-4) driven by the sequential opening and closing of voltage-gated Na⁺, Ca²⁺, and K⁺ channels. Phase 0 (rapid depolarization) is mediated by the inward Na⁺ current (Iₙₐ) through Nav1.5 channels encoded by SCN5A. Phase 1 (early repolarization) is shaped by the transient outward K⁺ current (Iₜₒ), carried by Kv4.2 (KCND2) and Kv4.3 (KCND3) channels. Phase 2 (plateau) is sustained by L-type Ca²⁺ current (I_{Ca,L}) through Cav1.2, modulated by calmodulin (CALM1-3). Phase 3 (repolarization) is driven by the rapid and slow delayed rectifier K⁺ currents (Iₖᵣ, Iₖₛ) via KCNH2 and KCNQ1, respectively, and the inward rectifier K⁺ current (Iₖ₁) via Kir2.1 (KCNJ2). Phase 4 (resting membrane potential) is set primarily by Iₖ₁. Any alteration in the expression, function, or regulation of these channels, whether by mutation, autoantibody, drug, or inflammatory mediator, disrupts the action potential waveform and creates an arrhythmogenic substrate ^[2]D5[29]D5.

Mechanisms of Channelopathy and Arrhythmogenesis

Loss-of-function in Na⁺ channels (SCN5A) reduces Iₙₐ, slowing conduction and predisposing to Brugada syndrome and progressive conduction defects; gain-of-function prolongs phase 2 via sustained late Na⁺ current, causing LQT3, and can also produce multifocal ectopic Purkinje-related premature contractions (MEPPC) ^[25]D5. Gain-of-function in K⁺ channels accelerates repolarization, shortening the action potential duration (APD) and the refractory period. An activating KCND2 mutation (p.S447R) increases Iₜₒ, abbreviating APD and predisposing to nocturnal paroxysmal atrial fibrillation ^[22]C4. Similarly, a de novo KCND3 mutation (Gly306Ala) augments Iₜₒ, causing early repolarization syndrome with J-point elevation and ventricular fibrillation ^[30]C4. Loss-of-function in K⁺ channels delays repolarization, prolonging APD and the QT interval. The KCNH2 mutant breakdance in zebrafish recapitulates LQT2 with prolonged APD, early afterdepolarizations, and 2:1 atrioventricular block ^[20]D5. Calmodulinopathies, mutations in CALM1-3, disrupt Ca²⁺-dependent modulation of Cav1.2 and the ryanodine receptor RyR2, producing severe LQTS and catecholaminergic polymorphic ventricular tachycardia (CPVT) ^[26]D5.

Beyond genetics, autoantibodies against K⁺ channels (e.g., anti-Kv1.4) can mimic genetic channelopathies by reducing repolarizing currents, and inflammatory cytokines such as TNF-α and IL-6 downregulate K⁺ channel expression, prolonging APD and increasing arrhythmic risk ^[28]D5[24]D5. Drug-induced toxicity is well illustrated by loperamide, which at high doses blocks Iₖᵣ and Iₙₐ, causing QT prolongation, QRS widening, and torsades de pointes ^[4]D5. Gap junctional uncoupling, as demonstrated by carbenoxolone, slows conduction velocity by 27% in the right atrium and 23% in the right ventricle without affecting refractoriness, highlighting the role of reduced intercellular coupling in arrhythmogenesis ^[21]C4. Finally, microRNA-1 can directly bind to and inhibit Kir2.1 (Iₖ₁) via a non-canonical biophysical mechanism, depolarizing the resting membrane potential and prolonging final repolarization; an arrhythmia-associated single-nucleotide polymorphism disrupting this interaction eliminates its proarrhythmic effect ^[19]D5.

These mechanistic insights directly inform therapy: quinidine blocks Iₜₒ and suppresses VF in early repolarization syndrome ^[30]C4, flecainide rescues MEPPC by blocking Iₙₐ ^[25]D5, and small-molecule screens identified flurandrenolide and 2-MMB as shortening APD in LQT2 via glucocorticoid receptor signaling ^[20]D5.

Principal Ion Currents and Associated Channelopathies

Pearl: When evaluating a patient with unexplained syncope or arrhythmia, consider the mechanistic overlap: genetic, autoimmune, and drug-induced channelopathies can produce identical APD phenotypes, QT prolongation or shortening, and the correct diagnosis hinges on careful history, ECG pattern, and targeted genetic or serologic testing, as treatment differs radically (e.g., flecainide for MEPPC, quinidine for ERS, avoidance of QT-prolonging drugs for LQT2).

Action potential abnormalities, whether inherited or acquired, present with a shared clinical signature of syncope, palpitations, and sudden cardiac arrest, often without structural heart disease ^[2]D5[6]D5. The presentation is governed by the specific ion channel defect: prolonged repolarization in long QT syndrome (LQTS) creates a substrate for early afterdepolarizations and torsades de pointes, while the loss of the sodium channel current in Brugada syndrome predisposes to ventricular fibrillation at rest ^[2]D5[5]D5. Catecholaminergic polymorphic ventricular tachycardia (CPVT) manifests as exercise- or emotion-induced bidirectional ventricular tachycardia driven by calcium overload ^[2]D5. Drug-induced forms, such as loperamide toxicity, produce recurrent syncope with marked QT prolongation and QRS widening ^[4]D5.

Presenting Symptoms

Patients typically present with syncope (often exertional in LQTS type 1, emotional in type 2, or during sleep in type 3), palpitations, presyncope, or aborted sudden cardiac arrest ^[2]D5[4]D5. The first symptom may be sudden death in up to 10-30% of cases, underscoring the need for early recognition ^[6]D5. Symptoms often begin in childhood or adolescence but can manifest later, especially with drug exposure or electrolyte disturbances ^[2]D5. In CPVT, the hallmark is stress-induced syncope without QT prolongation. In drug-induced (e.g., loperamide) toxicity, patients report recurrent syncope with accompanying ECG abnormalities ^[4]D5.

Examination Findings

The physical examination is often normal, making the 12-lead ECG the central tool. Irregular pulse may be noted during arrhythmias, but auscultation typically reveals no murmur. Family history of sudden cardiac death , unexplained accidents, or seizures is a critical clue ^[1]D5[2]D5. A thorough neurological exam may reveal no focal deficits, distinguishing syncope from seizure.

Phenotypic Variants

Red Flags

• Syncope during exercise or emotion (LQTS, CPVT)
• Family history of sudden cardiac death before age 40 ^[1]D5
• Drug-induced QT prolongation with palpitations or syncope ^[4]D5
• Seizure-like episodes that are actually convulsive syncope from arrhythmias ^[2]D5

Atypical Presentations

Up to 30% of patients with channelopathies are initially misdiagnosed with epilepsy, vasovagal syncope , or anxiety ^[2]D5[6]D5. Seizure-like activity due to cerebral hypoperfusion from torsades de pointes may be mistaken for epilepsy. A high index of suspicion and a low-threshold ECG are essential in young patients with unexplained syncope.

Pearl: Family history of sudden death and drug exposure are critical red flags.

The clinical presentation of syncope or cardiac arrest in a young patient with a normal heart prompts a systematic evaluation for an underlying channelopathy. The diagnostic process relies on a combination of clinical history, electrocardiographic recording, and genetic testing, as no single test is universally sensitive ^[1]D5[2]D5.

History and Clinical Suspicion

A detailed history should elicit the circumstances of syncope (exercise, emotion, fever, or no trigger), a family history of sudden cardiac death or unexplained accidents, and a medication history including nonprescription agents such as loperamide, which can cause QT prolongation and torsades de pointes in high doses ^[4]D5. Red flags include syncope during exertion in a young person (suggestive of catecholaminergic polymorphic ventricular tachycardia [CPVT] or long QT syndrome [LQTS] type 1) and syncope while sleeping or at rest (suggestive of Brugada syndrome [BrS] or LQTS type 3). Fever is a recognized trigger for BrS, and type 1 ECG pattern may appear only during febrile episodes, even with low-grade fever ^[33]C4.

Electrocardiographic Diagnosis

A 12-lead ECG is the cornerstone of diagnosis. QTc prolongation (≥460 ms in women, ≥450 ms in men) using Bazett's formula is the hallmark of LQTS, but the QT interval must be measured carefully in lead II or V5, and a single normal ECG does not exclude the diagnosis ^[2]D5. Ambulatory monitoring and exercise testing can unmask QT prolongation that appears only during recovery. For BrS, the type 1 Brugada pattern (coved ST-segment elevation ≥2 mm in leads V1-V3) is diagnostic; it may be transient and can be provoked by fever or sodium channel blockers (e.g., ajmaline, flecainide) ^[2]D5[33]C4. For CPVT, the resting ECG is usually normal, but exercise testing or catecholamine infusion reveals bidirectional ventricular tachycardia ^[2]D5. Short QT syndrome (SQTS) is identified by a QTc <330-360 ms, often with tall peaked T waves ^[2]D5[5]D5.

Genetic Testing

Genetic testing is recommended for all patients with a definite or suspected channelopathy, as it can confirm the diagnosis, guide risk stratification, and inform family screening ^[1]D5[2]D5. Targeted sequencing of genes encoding ion channel subunits (e.g., KCNQ1, KCNH2, SCN5A, RYR2) is the standard approach. However, 20-30% of patients with clinically definite BrS have no identifiable mutation in SCN5A after initial testing, and expanded sequencing (e.g., whole exome) may identify novel variants in genes such as CACNA1C (Timothy syndrome) or SCN10A ^{[2]D5[6]D5[32]C4[33]C4}. A negative genetic test does not rule out a channelopathy; clinical diagnosis remains the gold standard ^[1]D5[6]D5.

Laboratory and Imaging

Routine laboratory studies should include serum electrolytes (potassium, magnesium, calcium) to exclude acquired causes of QT prolongation, and thyroid function tests. For drug-induced LQTS, a toxicology screen for QT-prolonging agents (e.g., loperamide, methadone, antipsychotics) is indicated ^[4]D5. Echocardiography is performed to exclude structural heart disease, which is absent in primary channelopathies. Cardiac MRI may be considered if structural disease is suspected ^[2]D5.

Diagnostic Algorithm

1. Clinical suspicion (unexplained syncope, cardiac arrest, family history of sudden death, ECG abnormalities)
2. 12-lead ECG with measurement of QTc and assessment for Brugada pattern
3. If ECG is nondiagnostic, perform ambulatory monitoring (24-48 h Holter) and exercise stress test
4. Consider provocative testing for BrS (fever or sodium channel blocker challenge) if type 1 pattern is suspected
5. Genetic testing (targeted panel for LQTS, BrS, CPVT, SQTS)
6. Family screening (ECG and genetic testing of first-degree relatives) ^[1]D5[2]D5

Differential Diagnosis

The differential for unexplained syncope and cardiac arrest includes structural heart disease ( hypertrophic cardiomyopathy , arrhythmogenic right ventricular cardiomyopathy, myocarditis ), electrolyte disturbances, and drug-induced arrhythmias. The absence of structural abnormalities on echocardiography and the presence of characteristic ECG patterns or genetic findings point to a channelopathy ^[6]D5.

Pearl: Provocative testing (fever, exercise, sodium channel blockers) can unmask transient ECG patterns.

Once the diagnosis of a channelopathy such as long QT syndrome (LQTS) or Brugada syndrome (BrS) is established, validated severity grades and prognostic scores guide the intensity and timing of therapy. Risk stratification in LQTS depends primarily on genotype, baseline QTc duration, and sex. A QTc of 500 ms or more combined with LQT1, LQT2, or LQT3 genotype (and male sex) confers a ≥50% risk of a first cardiac event before age 40 ^[39]D5. Women with LQTS carry a higher risk of torsades de pointes, particularly in the postpartum period, due to shorter QTc intervals at slower heart rates in men ^[39]D5. In BrS, a spontaneous type 1 ECG pattern, syncope, and a family history of sudden cardiac death are the strongest predictors of arrhythmic events ^[36]D5. The presence of a pathogenic SCN5A mutation further stratifies risk, although monogenic inheritance is detected in <25% of cases ^[36]D5. Fever-induced Brugada pattern, even low-grade subfebrile episodes (body temperature <38.5°C), can unmask the type 1 ECG in susceptible patients and should prompt aggressive antipyretic therapy and monitoring ^[33]C4.

Drug-Induced QT Prolongation Risk Assessment

For acquired QT prolongation, risk stratification tools incorporate clinical factors (age, female sex, heart disease, hypokalemia, baseline QTc ≥450 ms) and the proarrhythmic potential of the offending drug. The hERG (human Ether-à-go-go-Related Gene) channel is the primary target; computational models such as Pred-hERG 5.0 predict blockade with high accuracy, providing binary classification, multiclass probability, and pIC50 regression estimates ^[37]D5. Structural alerts for QT-prolonging drugs include amines, ethers, and aromatic compounds; these moieties appear in large quantities in QT-prolonging drugs but rarely in safe drugs, enabling a structure-activity model that achieves recall rates of 72.5-80.0% ^[38]D5.

Genotype-Directed Risk Scores

Pearl: In LQTS, a QTc ≥500 ms together with LQT1-3 genotype carries a >50% risk of a first cardiac event by age 40; in BrS, a spontaneous type 1 ECG plus syncope identifies patients with the highest arrhythmic risk and mandates ICD implantation ^[36]D5[39]D5.

Once risk stratification identifies a patient at high risk for life-threatening arrhythmias due to cardiac action potential (AP) abnormalities, immediate intervention targets the underlying ion channel dysfunction. The acute management approach is guided by the specific etiology, drug-induced QT prolongation, congenital long QT syndrome (LQTS), or ibrutinib-related cardiotoxicity, and relies on a stepwise protocol integrating withdrawal of offending agents, electrolyte correction, and targeted pharmacologic or emerging biologic therapies.

Step 1: Initial Assessment and Severity Classification

• ECG and laboratory evaluation: Measure QT interval corrected for heart rate (QTc), serum potassium, magnesium, and calcium. A QTc >500 ms or an increase >60 ms from baseline signals high risk for torsades de pointes (TdP) ^[50]D5 (5).
• Identify the offending agent: For drug-induced QT prolongation, review all medications including antimalarials ( pyronaridine , artesunate ) that may prolong the AP duration ^[47]D5 (5). For patients on ibrutinib, assess for new ventricular arrhythmia vulnerability ^[43]D5 (5).
• Risk stratification: Patients with congenital LQTS (genotype-positive) or those with a history of syncope, family history of sudden cardiac death , or QTc >500 ms are classified as high risk ^[1]D5 (5).

Step 2: First-Line Intervention

• Withdrawal of culprit drugs: Immediately discontinue any agent known to prolong the QT interval. For antimalarials, the Comprehensive in vitro Proarrhythmia Assay (CiPA) classifies pyronaridine and artesunate as low risk at therapeutic free concentrations, but supratherapeutic levels may pose intermediate risk ^[47]D5 (5).
• Correction of electrolytes: Administer intravenous magnesium sulfate (2 g) for TdP, followed by potassium repletion to maintain serum K+ >4.5 mEq/L.
• SGK1 inhibition for drug-induced QT prolongation: In preclinical models, serum and glucocorticoid regulated kinase-1 (SGK1) inhibitors (SGK1-I1 30 nM, SGK1-I2 300 nM) attenuate dofetilide-induced APD90 prolongation by 72% and 90%, respectively, compared with 46% attenuation by mexiletine 10 mM ^[50]D5 (5). These agents are not yet approved but represent a promising acute strategy.
• AMPK activation for ibrutinib-induced arrhythmia: The Bruton’s tyrosine kinase inhibitor ibrutinib increases ventricular arrhythmia inducibility (72.2% vs 38.9% in controls; P<0.002) and shortens AP duration. Acute treatment with the AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) reduces inducibility to 37.1% (P<0.05) ^[43]D5 (5).

Step 3: Second-Line Interventions

• Beta-blockers with Kv4.3-blocking activity: Carvedilol (100 μM) inhibits the transient outward potassium current (Ito) by 77% for the Kv4.3 L isoform and 67% for the Kv4.3 S isoform; metoprolol is less potent (37% and 35%, respectively), while bisoprolol has no effect ^[45]D5 (5). In acute settings, carvedilol may be preferred for its additional Ito blockade.
• Optogenetic termination of atrial tachyarrhythmias: In transgenic mouse hearts, brief pulsed blue light stimulation (470 nm, 10 ms, 16 mW/mm²) terminates atrial tachyarrhythmia with 68% efficacy by prolonging the effective refractory period via channelrhodopsin-2 activation ^[49]D5 (5). This experimental approach could become a future acute therapy.

Step 4: Monitoring and Titration

• Continuous telemetry with QT interval monitoring every 15 minutes during acute intervention. For patients receiving SGK1 inhibitors (if available), monitor APD90 on voltage-sensing dye if using iPSC-CM models ^[50]D5 (5).
• For ibrutinib-treated patients, assess for spontaneous intracellular Ca2+ elevations and beat-to-beat alternans ^[43]D5 (5).

Step 5: Transition to Long-Term Management

• Once acute stabilization is achieved, patients are referred for long-term guideline-directed therapy (Section 8), which may include beta-blockers, implantable cardioverter-defibrillator placement, or novel gene therapy approaches such as suppression-replacement (SupRep) KCNQ1 or KCNH2 constructs that normalize APD in LQT1 and LQT2/SQT1 ^[40]D5[51]D5 (5).

Drug Modality Comparison Table

Controversies and Guideline Disagreement

No major guideline disagreements identified for this topic in the reviewed evidence. The acute management of AP disorders remains primarily driven by standard electrolyte correction and drug withdrawal, with novel therapies under investigation.

Pearl: In acute drug-induced QT prolongation, SGK1 inhibitors show >90% APD90 attenuation in preclinical models, suggesting a future role beyond standard magnesium and potassium repletion ^[50]D5 (5).

Once acute arrhythmia is controlled, the focus shifts to chronic suppression of the arrhythmic substrate and prevention of sudden cardiac death . For inherited channelopathies, long-term management is guided by genotype-specific risk stratification and the use of β-blockers, sodium channel blockers, and, in selected high-risk cases, device therapy or emerging gene-based interventions ^[2]D5 (5).

Beta-Adrenergic Blockers

β-blockers are the cornerstone of long-term therapy for long QT syndrome type 1 (LQT1) and catecholaminergic polymorphic ventricular tachycardia ( CPVT ). The Nature Reviews Disease Primers 2020 review recommends propranolol and nadolol as the preferred agents, based on their efficacy in reducing adrenergic-triggered arrhythmic events ^[2]D5 (5). In vitro studies further demonstrate that carvedilol blocks the cardiac Kv4.3 channel (the transient outward current Ito) by 77±2% at 100 µM, while metoprolol blocks by 37±3% and bisoprolol shows no effect, suggesting that carvedilol's additional Kv4.3 blockade may contribute to antiarrhythmic benefit in failing hearts ^[45]D5 (5). The optimal dose is titrated to a resting heart rate of 50-60 bpm, though specific dose ranges are not reported in the guideline-level evidence. NNT for preventing syncope or sudden death is not calculable from the available data.

Sodium Channel Blockers

Quinidine , a sodium and transient outward current blocker, is recommended for Brugada syndrome patients who have recurrent ventricular arrhythmias or are ineligible for ICD implantation ^[2]D5 (5). Mexiletine is used as a comparator in preclinical studies of drug-induced QT prolongation; in human iPSC-cardiomyocytes, 10 mM mexiletine shortened the pathologically prolonged action potential duration (APD90) from 673±8 ms to 563±8 ms (46% attenuation) ^[50]D5 (5). Despite this, mexiletine’s clinical role in LQT3 is supported by observational data, but no landmark trial within the reviewed evidence establishes its superiority. NNT not calculable from reported data.

Potassium Channel Modulators

Amiodarone and sotalol are broad-spectrum potassium channel blockers but are not first-line for inherited channelopathies due to proarrhythmic risk. The KCNH2 -related short QT syndrome is an exception; experimental gene therapy discussed below may offer a more targeted approach ^[51]D5 (5).

Gene Therapy and Emerging Targeted Therapies

Several novel therapies aim to correct the underlying ion channel defect directly. These are summarized in the table below and represent a paradigm shift from symptomatic suppression to molecular repair.

These therapies are not yet approved for clinical use, but they provide proof-of-concept for mutation-independent and mutation-specific correction of action potential abnormalities.

Device Therapy and Surgical Interventions

For patients with high-risk features (e.g., prior cardiac arrest, recurrent syncope despite β-blockade, or LQT3 with early repolarization), implantable cardioverter-defibrillators (ICDs) and left cardiac sympathetic denervation (LCSD) are effective options ^[2]D5 (5). Their detailed indications, outcomes, and procedural considerations are covered in the following section on Interventional and Device Therapy.

Controversies and Guideline Disagreement

No major guideline disagreements identified for this topic in the reviewed evidence.

Pearl: For LQT1 and CPVT, β-blockers (propranolol, nadolol) remain first-line; for BrS and LQT2/LQT3, sodium channel blockers or gene-based therapies may be considered based on genotype and risk stratification, with emerging gene therapy offering the first potential for molecular cure in preclinical models ^{[40]D5[51]D5[54]D5}.

Having established the role of guideline-directed medical therapy, the next step for patients with drug-refractory arrhythmias or an identifiable substrate is interventional electrophysiology. Catheter ablation directly targets the arrhythmogenic source, while advanced mapping techniques such as electrocardiographic imaging (ECGI) provide noninvasive characterization of repolarization abnormalities.

Catheter Ablation for Atrial Fibrillation

Pulmonary vein isolation (PVI) is the cornerstone of AF ablation, but additional substrate modification may be required in persistent AF. Left atrial anatomical variations influence the location of non-PV sources. In a study of 30 patients undergoing radiofrequency catheter ablation, a non-abutting left atrial appendage (LAA) and left superior pulmonary vein (LSPV) (distance > 2 mm) was associated with the presence of a leading AF source near the LA ridge (7 of 11 vs 3 of 19, p = 0.01) ^[58]B3b. This suggests that preprocedural CT imaging to identify LAA-LSPV configuration may help guide mapping and ablation strategy.

Catheter Ablation for Ventricular Arrhythmias

In patients with monomorphic ventricular tachycardia, ablation targets scar-related reentrant circuits. However, for certain inherited arrhythmia syndromes , the approach differs. Multifocal ectopic Purkinje-related premature contractions (MEPPC) syndrome, caused by SCN5A gain-of-function variants, presents with a high burden of PVCs and dilated cardiomyopathy. Catheter ablation is relatively ineffective because the PVCs originate from all parts of the fascicular Purkinje fiber network ^[25]D5. Instead, class Ic sodium channel inhibitors, notably flecainide, are remarkably effective at reducing ectopic burden and reversing cardiomyopathy. This highlights the importance of genetic testing to identify the arrhythmia mechanism before proceeding with ablation.

Electrocardiographic Imaging (ECGI)

ECGI is a noninvasive modality that reconstructs epicardial potentials and repolarization maps. In normal human hearts, repolarization is spatially homogeneous with a dispersion of 40 ms between the right and left ventricles ^[59]D5. ECGI can detect abnormal repolarization gradients, such as the large base-to-apex gradient seen in Wolff-Parkinson-White syndrome (cardiac memory) that resolves after successful ablation ^[59]D5. This capability makes ECGI a potential tool for noninvasive risk stratification and for evaluating the effects of drugs and devices on repolarization.

Pearl: Catheter ablation is effective for focal arrhythmias but fails in diffuse Purkinje system disorders like MEPPC, where flecainide is the first-line therapy; preprocedural anatomical and genetic characterization improves patient selection.

While interventional approaches such as catheter ablation and ICD implantation directly address arrhythmia substrates, the pharmacological modulation of the cardiac action potential has been the cornerstone of antiarrhythmic therapy for decades. The evolution of this therapy reflects a cycle of discovery, clinical success, recognition of proarrhythmia, and refinement, a trajectory that continues today with computational safety prediction.

The Rise of Class III Agents

In the 1980s, drugs that prolong the cardiac action potential (Vaughan Williams Class III) emerged as a promising strategy to suppress re-entrant arrhythmias. Sotalol, a non-selective β‑blocker that also prolongs the action potential, was among the first. Its dextrorotatory isomer, d‑sotalol, was studied for its pure Class III effect. In a prospective randomized trial, d‑sotalol (1, 1.5 or 2 mg/kg IV) produced dose‑dependent prolongation of the QT and QTc intervals and increased atrial and ventricular effective refractory periods, with a linear correlation between plasma sotalol level and QT change (r = 0.86, p = 0.001) ^[66]A1b.

However, clinical experience revealed the dark side of action‑potential prolongation: torsade de pointes. In a randomized trial of sotalol for prevention of supraventricular arrhythmias after CABG , adverse effects (bradycardia < 50 bpm, systolic BP < 90 mmHg, or cardiac index < 2.2 L/min/m²) forced discontinuation in 24% of patients receiving the loading infusion, and the incidence of arrhythmias did not differ significantly from controls ^[69]A1b. The landmark SWORD trial (not in present references) subsequently showed that d‑sotalol increased mortality, effectively ending interest in pure Class III agents for most indications.

Amiodarone : A Multichannel Solution

Amiodarone broke the mold. Though predominantly a Class III agent, it also possesses Class I, II, and IV properties, which dampen the risk of proarrhythmia while preserving efficacy ^[67]D5. Its primary mechanism, prolonging the action potential and repolarization time, increases the refractory period and reduces membrane excitability ^[67]D5. The ARREST trial randomized patients with out‑of‑hospital cardiac arrest to IV amiodarone or placebo and found a significant improvement in survival to emergency department arrival ^[67]D5. Amiodarone became the first‑line agent for acute treatment of life‑threatening ventricular arrhythmias and remains the most effective antiarrhythmic for maintaining sinus rhythm in atrial fibrillation , albeit with a burden of extracardiac toxicity that limits long‑term use.

Proarrhythmia and the hERG Safety Paradigm

The recognition that many drugs prolonged the QT interval by blocking the hERG potassium channel (I_Kr) led to a systematic re‑evaluation of drug safety. A landmark analysis of 100 drugs found that those associated with torsade de pointes had hERG IC₅₀ values close to or overlapping the free therapeutic plasma concentration (ETPC_unbound) ^[75]D5. For drugs with a >30‑fold margin between C_max and hERG IC₅₀, the risk of TdP was very low, though exceptions (e.g., verapamil , with a 1.7‑fold margin but no QT prolongation) highlighted the importance of multichannel interactions ^[75]D5. This safety margin became a regulatory benchmark, and several drugs, including cisapride and terfenadine, were withdrawn from the market because they fell short.

Treatment of Inherited Channelopathies

For patients with long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia, and Brugada syndrome , therapy targets the specific ionic defect. β‑adrenergic receptor blockers, specifically propranolol and nadolol, are first‑line for LQTS, reducing the risk of cardiac events. For Brugada syndrome, quinidine (a sodium and transient outward current blocker) is used for arrhythmia suppression. When pharmacological therapy is insufficient, left cardiac sympathetic denervation and ICD implantation are employed ^[2]D5.

The Future: In Silico Safety Prediction

Contemporary drug development has moved toward computational prediction of proarrhythmia. The Comprehensive in vitro Proarrhythmia Assay (CiPA) paradigm integrates humanized cardiomyocyte models and mathematical modeling to assess the proarrhythmic risk of new compounds, replacing the simplistic reliance on hERG IC₅₀ alone ^[76]D5. These models incorporate the complex interplay of multiple ion channels, restitution properties, and dynamic conditions such as ischemia ^{[68]D5[71]D5[76]D5}.

Pearl: The history of antiarrhythmic therapy teaches that prolonging the action potential is a double‑edged sword, the same mechanism that suppresses re‑entry can create the substrate for torsade de pointes, a lesson that continues to shape drug development and clinical prescribing.

These treatment advances notwithstanding, the action potential itself remains a substrate for complications that arise from both the underlying channelopathy and the therapies used to modify it.

Autonomic and Arrhythmic Complications

Arrhythmias are the most direct complication. Gain-of-function mutations in KCND2 abbreviate action potential duration, creating substrate for nocturnal atrial fibrillation ^[22]C4. QT-prolonging drugs (e.g., loperamide ) precipitate torsades de pointes via block of IKr ^[4]D5. Cocaine produces both sodium channel blockade and catecholamine excess, driving ventricular tachycardia and fibrillation ^[15]D5. Fever in Brugada syndrome reduces sodium channel conductance, unmasking type 1 pattern in 20-30% of patients ^[33]C4. Ischemia induces action potential alternans, a precursor to reentrant arrhythmias ^[71]D5. Antiarrhythmic therapy itself carries proarrhythmic risk: class Ic agents are contraindicated after myocardial infarction, and amiodarone 's long-term toxicity limits its use ^[80]D5.

Hemodynamic Instability and Metabolic Disturbances

Sustained arrhythmias impair cardiac output, causing syncope or sudden cardiac death ^[2]D5. In heart failure, NCX upregulation impairs mitochondrial bioenergetics, contributing to energy starvation and worsening contractility ^[77]D5. Combined electrolyte depletion (K, Ca, Mg) prolongs repolarization and can trigger arrhythmias ^[79]C4.

Drug-Induced Conduction Slowing

Carbenoxolone , a gap junction uncoupler, reduces conduction velocity by 27% in atrium and 23% in ventricle without affecting refractoriness, facilitating reentry ^[21]C4.

Supportive Care

• DVT/PE Prophylaxis: Standard with enoxaparin 40 mg subcutaneously daily or equivalent low-molecular-weight heparin during immobilization.
• Pain Management : For cocaine-induced chest pain, sodium bicarbonate 1-2 mEq/kg IV reverses QRS widening ^[15]D5. For ICD shocks, consider anxiolytics.
• Rehabilitation: Early mobilization after arrhythmia stabilization.
• Hospital-Acquired Complications: Prevent pneumonia, pressure injury, and UTI with standard ICU bundles.

Complication Table

Pearl: In any patient with unexplained syncope, ECG abnormalities, or arrhythmia, consider loperamide misuse, electrolyte depletion, and fever as reversible triggers of action potential-mediated complications.

Having established the arrhythmic and ischemic complications of action potential (AP) derangements, the natural history of these abnormalities determines the trajectory of disease progression.

Untreated Natural History

AP abnormalities in channelopathies, e.g., congenital long QT syndrome , carry a high risk of sudden cardiac death (SCD), especially in young patients with syncope ^[83]D5. In ischemic heart disease, persistent activation of the late sodium current (late INa) prolongs AP duration, promoting early afterdepolarizations and torsades de pointes ^[78]D5[85]D5. Sepsis-induced AP prolongation correlates with myocardial injury and elevated IL-6, CK-MB, and sST2 levels ^[86]D5.

Validated Predictors

QT interval >500 ms on ECG is the most established predictor of arrhythmic risk in both congenital and acquired settings. Circulating cardiac miRNAs (miR-1, miR-133a) are elevated in acute MI and predict adverse left ventricular remodeling ^[7]D5. The interaction between connexin 43 (Cx43) and ATP-sensitive potassium (KATP) channels may identify patients with greater ischemic preconditioning capacity ^[82]D5.

Treatment-Modified Outcomes

Ranolazine, by inhibiting late INa, reduces infarct size and ischemia/reperfusion arrhythmias in animal models ^[78]D5; in humans, it improves angina symptoms but does not reduce mortality or recurrent MI (MERLIN- TIMI 36) ^[84]D5. Tropisetron, a 5-HT3 antagonist, attenuates AP prolongation and suppresses inflammatory markers in sepsis, potentially improving outcomes ^[86]D5. In congenital long QT syndrome, β-blockers and ICDs reduce SCD risk from approximately 50% to less than 5% ^[83]D5.

Pearl: A QT interval >500 ms carries a 2- to 3-fold increased risk of torsades de pointes; combined with hypokalemia or hypomagnesemia, the risk escalates further and warrants urgent correction.

While the natural history of arrhythmias is well-documented, the cardiac action potential itself undergoes age- and disease-dependent remodeling that alters arrhythmia susceptibility in specific populations. The available evidence focuses predominantly on elderly patients and those with diabetes, where molecular changes in ion channel expression have been directly measured.

Elderly

Ageing of the heart is accompanied by progressive loss of the dominant pacemaker function of the sinoatrial node, leading to ' sick sinus syndrome ' characterised by fainting, palpitations, shortness of breath and sudden death ^[89]D5. This failure of the normal heartbeat is attributed to depletion of connexin 43, a gap junction protein essential for electrical coupling between cardiac cells, which leaves the pacemaker disconnected and unable to drive the heart ^[89]D5. In elderly patients with type 2 diabetes, additional pro-arrhythmogenic gene remodelling occurs independently of left ventricular hypertrophy or fibrosis: left ventricular myocardial expression of KCNH2 (the gene encoding the rapid delayed rectifier K⁺ current, I_Kr) is downregulated, while SLC8A1 (encoding the Na⁺-Ca²⁺ exchanger, NCX1) is upregulated ^[87]B3b. These changes prolong the action potential duration and promote early after-depolarisations, manifested clinically as a prolonged QT interval on the standard ECG ^[87]B3b. Mathematical modelling confirms that reduced I_Kr density and increased NCX1 current create a substrate for ventricular arrhythmogenesis ^[87]B3b.

Diabetes

Type 2 diabetes independently increases ventricular arrhythmia risk, and the aforementioned gene expression changes provide a molecular mechanism. Compared with control patients with comparable left ventricular hypertrophy and possible myocardial fibrosis, the diabetes group showed lower KCNH2 and KCNJ3 expression and higher KCNJ2, KCNJ5 and SLC8A1 expression ^[87]B3b. These alterations are detectable before overt structural heart disease develops, indicating that chronic hyperglycaemia directly impacts the cardiac action potential ^[87]B3b.

Drug-Induced Vulnerabilities

Benzodiazepines interact with peripheral benzodiazepine receptors (TSPO) which may influence calcium ion channels, affecting cardiac action potential and contractility ^[88]D5. Discontinuation of these medications can potentially trigger atrial fibrillation through unresolved mechanisms involving calcium channel modulation; however, causality remains uncertain ^[88]D5. Clinicians should be aware of this possible risk when deprescribing long-term benzodiazepines, particularly in elderly patients with pre-existing cardiac vulnerability.

Pediatrics

No direct human studies have quantified cardiac action potential remodelling in the paediatric population. Developmental changes in ion channel expression are presumed to underlie age-dependent differences in action potential duration, rate adaptation, and susceptibility to inherited arrhythmia syndromes , but molecular evidence in children is absent from the current literature.

Pregnancy

Pregnancy-related hormonal changes (oestrogen, progesterone) are known to affect cardiac ion channels, but specific alterations in human myocardial gene expression during pregnancy have not been reported in the sourced evidence. No data are available on action potential modifications or arrhythmia risk stratification unique to pregnancy.

Immunocompromised

The immunocompromised population (HIV, transplant recipients, chronic immunosuppression therapy) has not been studied for direct action potential gene expression changes. Indirect effects from drug interactions (e.g., macrolide antibiotics , azole antifungals) that prolong the QT interval are well recognised but fall outside the scope of this section's evidence base.

Prevention of Age-Related Arrhythmogenic Remodeling

Simple interventions such as regular exercise may preserve connexin 43 expression and maintain electrical stability of the ageing heart, potentially reducing the incidence of sick sinus syndrome without pharmacological manipulation ^[89]D5. In diabetic patients, strict glycaemic control could theoretically attenuate the pro-arrhythmogenic gene expression changes, although this has not been tested in prospective trials. No pharmacological agents are currently proven to reverse age-related action potential remodelling.

Pearl: In elderly patients with diabetes and no structural heart disease, a prolonged QT interval should raise suspicion for underlying KCNH2 downregulation and increased Na⁺-Ca²⁺ exchange, a reversible risk factor that may respond to exercise and improved glycaemic control.